Company intelligence / Profile preview
Aurobac Therapeutics
Lyon, Franceaurobac-tx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Lead asset ATX101 has shown promising preclinical data targeting vascular integrity loss in septic shock. The company’s pipeline includes multiple preclinical/discovery programs against Gram-negative pathogens. No clinical results yet as first-in-human studies are planned for the near future.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (ATX101 and others)Precision drugs/therapeuticsDiagnostic-driven approaches
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Boehringer IngelheimEvotec SEbioMérieux SAOngoing collaborations on diagnostics and therapeutics development
Beyond the preview
Go deeper on Aurobac Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aurobac Therapeutics.